BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 50%* for Ultimate Trader

1 year 30%, 2 years 40% and *3 years 40%

*Across 3 years $3395.52 only $1697.76

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,046.42
0.79%
US Tech 100
20,642.37
1.24%
Dow Jones
44,749.93
-0.36%
Brent Oil
71.675
-0.55%
Bitcoin
95,312.00
-1.99%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Purple Biotech Ltd (PPBT)

  7. Purple Biotech Ltd (PPBT) News

Purple Biotech Ltd

Purple Biotech Ltd (PPBT)

NASDAQ
8.735
5.38
( 160.36% )
Updated: 12:17:48
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

PPBT News

Official News Only

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
5 hours ago
PPBT (160.36%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
November 15 2024
PPBT (160.36%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
November 04 2024
PPBT (160.36%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 25 2024
PPBT (160.36%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 10 2024
PPBT (160.36%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 09 2024
PPBT (160.36%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 02 2024
PPBT (160.36%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
September 18 2024
PPBT (160.36%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
September 11 2024
PPBT (160.36%)

PPBT Discussion

View Posts
tedpeele tedpeele 11 minutes ago
crazy - I guess due to small float. I'm out for now. good day. good luck to you.
👍️0
TheFinalCD TheFinalCD 1 hour ago
too many

https://www.nasdaqtrader.com/trader.aspx?id=tradehalts
👍️0
tedpeele tedpeele 1 hour ago
lots of halting
👍️0
TheFinalCD TheFinalCD 2 hours ago
$13's
👍️0
TheFinalCD TheFinalCD 2 hours ago
6.27 halted up

https://x.com/THIS_TIME_X/status/1863603210973298718
👍️0
TheFinalCD TheFinalCD 4 hours ago
https://x.com/THIS_TIME_X/status/1863568226573066260
👍️0
tw0122 tw0122 5 hours ago
Looking good $5s + 50% for this low floater pancreatic cancer phase 2
👍️0
TheFinalCD TheFinalCD 5 hours ago
PPBT https://x.com/OzmosiHealth/status/1863554233485898198

https://dilutiontracker.com/app/search/PPBT?a=dbb88c

https://finviz.com/quote.ashx?t=PPBT&p=d
👍️0
tw0122 tw0122 4 weeks ago
$3.10 down -1% low floater will gain some traction some warrants to watch 
👍️0
tw0122 tw0122 4 weeks ago
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of DeathNovember 04 2024 - 7:50AM


Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has identified serum CEACAM1 as an additional new potential blood biomarker that may help determine which metastatic pancreatic ductal adenocarcinoma (PDAC) patients are most likely to benefit from treatment with CM24. CM24 is a humanized monoclonal antibody that blocks CEACAM1 binding thereby inhibits its activity.  CEACAM1 is overexpressed on certain tumor cells, immune cells, and neutrophils extracellular traps (NETs).PDAC patients who had pretreatment serum CEACAM1 levels between 6K and 15K pg/mL  demonstrated the best outcomes following treatment with CM24 and nivolumab in combination with irinotecan/fluoropyrimidine based chemotherapy compared to chemotherapy control, with respect to both progression free survival (PFS) (median = 4.6 months, hazard ratio [HR] < 0.1, P = 0.003) and overall survival (OS) with an 79% reduction in risk of death (HR = 0.21, P = 0.04). The median OS improved from 3.6 months with chemotherapy alone to 8.7 months with the combination.Purple Biotech’s randomized Phase 2 study of CM24 in the second line treatment of PDAC has previously identified multiple potential biomarkers including another serum-based marker, myeloperoxidase (MPO), and tumor markers.“As we look ahead to topline Phase 2 results before the end of the year and anticipate advancing CM24 into further clinical development, the identification of an additional serum biomarker for patient selection is a critical advantage for our future CM24 study and more importantly, potentially for cancer patients in need of better outcomes, particularly for pancreatic cancer,” said Gil Efron, Purple Biotech CEO.
👍️0
fwb fwb 2 months ago
Usually in a R/S if a person has Less than 1 share, they are paid in cash.
and they are no longer a shareholder of the company.
That is what happen to many shareholders of ELCO Elcom International, Inc.
👍️0
Cosa Cosa 3 months ago
I bought 1 share back in 2021 just to keep track. It is -89%
👍️0
glenn1919 glenn1919 5 months ago
PPBT...........................................https://stockcharts.com/h-sc/ui?s=PPBT&p=W&b=5&g=0&id=p86431144783
👍️0
Boknows34 Boknows34 6 months ago
This thing is coming back to life…Finally
👍️ 1
Monksdream Monksdream 1 year ago
PPBT under $2
👍️0

Your Recent History

NASDAQ
PPBT
Purple Biotech
UNSW
LONETH
LON Token [Tokenlon]
LSE
SRUG
Ubsetf Srug
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 50%* for Small Cap Pro

1 year 30%, 2 years 40% and *3 years 50%

*Across 3 years $2158.56 only $1079.28